Lunai Bioworks plans Nasdaq delisting
- Lunai Bioworks (LNAI) received a Nasdaq delisting determination after failing to meet the exchange’s $2.5M minimum stockholders’ equity requirement.
- The company reported a stockholders’ deficit of $9.02M as of June 30, 2026.
- Trading in the company’s common stock is expected to be suspended at the opening of business on October 30, 2026.
- Lunai (LNAI) intends to file Form 25 with the SEC around November 2, with the delisting expected to become effective around November 12.
Recommended For You
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Create Your Free Account to Keep Reading
Get the confidence to navigate an uncertain market with free breaking news and stock alerts.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.